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Abstract
Purpose To determine the malignancy rate of bone lesions
identified on FDG PET/CT in patients who have undergone
CT-guided biopsy because of the suspicion of malignancy.
Methods This single-centre retrospective study spanned eight
consecutive years and included all patients who underwent
both FDG PET/CT and CT-guided bone biopsy because of
the suspicion of malignancy. The positive predictive value
(PPV) for malignancy was calculated, and different patient
and imaging characteristics were compared between malig-
nant and benign bone lesions.
Results Of 102 included patients with bone lesions that all
showed FDG uptake exceeding mediastinal uptake, bone bi-
opsy showed a malignant lesion in 91 patients, yielding a PPV
for malignancy of 89.2 % (95 % CI 81.7 – 93.9 %). In the 94
patients with bone lesions that showed FDG uptake exceeding
liver uptake, bone biopsy showed a malignant lesion in 83
patients, yielding a PPV for malignancy of 88.3 % (95 % CI
80.1 – 93.5 %). Higher age, bone marrow replacement of the
lesion seen on CT, expansion of the lesion seen on CT, and
presence of multifocal lesions on FDG PET/CT were
significantly more frequent in patients with malignant lesions
than in those with benign bone lesions (P=0.044, P=0.009,
P=0.015, and P=0.019, respectively). Furthermore, there
was a trend towards a higher incidence of cortical destruction
(P=0.056) and surrounding soft tissue mass (P=0.063) in
patients with malignant bone lesions.
Conclusion The PPV for malignancy of suspicious bone le-
sions identified on FDG PET/CT is not sufficiently high to
justify changes in patient management without histopatholog-
ical confirmation. Nevertheless, ancillary patient and imaging
characteristics may increase the likelihood of a malignant
bone lesion.
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Introduction
Bone metastases are a frequent complication of cancer, occur-
ring in up to 70 % of patients with advanced breast or prostate
cancer, and in approximately 15 – 30 % of patients with car-
cinoma of the lung, colon, stomach, bladder, uterus, rectum,
thyroid or kidney [1]. Timely and accurate detection of bone
metastatic disease is important for treatment planning and
prognostication. 18F-FDG PET/CT is currently regarded as
the most accurate cross-sectional whole-body imaging modal-
ity for the evaluation of many cancers, and is increasingly
being used for this purpose in clinical practice. The addition
of functional FDGPET information to anatomical CT findings
may improve the detection of malignant bone disease [2].
Nevertheless, histopathological examination remains the
method of choice for the final diagnosis of bone lesions that
are suspicious for malignancy. Biopsy under CT guidance
plays an important role in obtaining tissue for histopatholog-
ical examination of suspicious bone lesions identified on FDG
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PET/CT. Although percutaneous CT-guided bone biopsy is
generally regarded as a safe and effective procedure, it is still
burdensome to the patient, not completely risk-free and costly,
and there is a delay in diagnosis when the acquired specimen
has to be decalcified before it can be histologically examined
[3–5]. In addition, not every patient may be a candidate for
CT-guided biopsy due to physical or mental health issues.
In this context, it would be of interest to know what pro-
portion of suspicious bone lesions identified on FDG PET/CT
prove to be malignant on biopsy. Although it can be argued
that FDG uptake is not specific for malignancy, the diagnostic
yield of CT-guided biopsy of focal FDG-avid (i.e. FDG uptake
exceeding liver FDG uptake) bone lesions is still unknown.
Previous studies related to this topic lacked histopathological
correlation [6, 7] or suffered from a small sample size [8]. If
FDG PET/CTachieves a high positive predictive value (PPV),
the need for bone biopsy in every patient may be reconsidered.
The purpose of this study was therefore to determine the ma-
lignancy rate of bone lesions identified on FDG PET/CTwho
have undergone CT-guided biopsy because of the suspicion of
malignancy.
Materials and methods
Study design and patients
This retrospective study was approved by the local institution-
al review board and the requirement for written informed con-
sent was waived. The Picture Archiving and Communication
System (PACS) of the Meander Medical Center was searched
for all patients who had undergone both FDG PET/CT and
CT-guided biopsy between September 2007 and September
2015, and their records were reviewed to determine age, gen-
der, presence of bone pain, and reported weight loss. The start
date of September 2007 was chosen because this was when
integrated PET/CT replaced stand-alone PET at our institu-
tion. The Meander Medical Center is a large university-
affiliated general teaching hospital centrally located in
The Netherlands. It provides care to patients with almost all
types of cancer, with ample experience in the treatment of
breast, prostate, lung, colorectal, haematological, renal, ovar-
ian and gastric malignancies. However, patients with suspi-
cion of a primary malignant bone tumour are referred directly
to another institution with expertise in orthopaedic oncology
for diagnosis and treatment, and these patients were therefore
not included in this study.
Inclusion criteria for this study were: availability of a CT-
guided bone biopsy that was performed because of the suspi-
cion of malignancy and availability of a FDG PET/CT scan
within 1 month of CT-guided biopsy. Exclusion criteria were:
patients who underwent CT-guided bone biopsy because of
(suspicion of) infection or inflammation, therapy (either
radiation therapy or chemotherapy) between bone biopsy
and the FDG PET/CT scan, technically failed bone biopsy
(i.e. no bone tissue acquired), no clear histopathological diag-
nosis, and no or insufficient tissue for histopathological diag-
nosis as determined by the attending pathologist.
FDG PET/CT
All patients underwent integrated FDG PET/CT. Between
September 2007 and December 2013 a Biograph 40 TruePoint
system (Siemens Healthcare, Erlangen, Germany) was used,
and between January 2014 and September 2015 a Biograph
TruePoint TrueV system (Siemens) was used for FDG PET/
CT scanning. Patients fasted for at least 6 h and blood glucose
levels were checked to ensure that they were less than
11 mmol/L before intravenous injection of FDG ([3×weight
in kilograms] megabecquerels for the Biograph 40 TruePoint
and [0.0209×weight in kilograms2,047] megabecquerels for
the Biograph TruePoint TrueV). Approximately 60 min after
FDG administration, a 3D PET acquisition was initiated from
the mid-thigh to the skull base, in five to seven bed positions
(with 3 min per bed position). A low-dose CT scan was used
for transmission scanning, and the PET images were recon-
structed using a weighted iterative ordered-subsets expecta-
tion maximization algorithm. A contrast-enhanced full-dose
CT scan in the portal venous phase was performed as part of
the FDG PET/CT examination in 61 of 102 included patients
(59.8 %). In addition, all patients underwent a full-dose CT
scan in a separate session for CT-guided bone biopsy
planning.
FDG PET/CT evaluation
Using a PACS workstation (IMPAX 6.6.1.1527; AGFA,
Mortsel, Belgium), all FDG PET/CT images were evaluated
by an experienced reader (T.C.K.) who was blinded to the
clinical, laboratory, pathological and follow-up findings.
However, the reader was informed about the location of each
bone lesion for which CT-guided biopsy was performed. The
FDG uptake of each bone lesion was visually assessed using a
five-point grading scale: 1 no uptake, 2 uptake lower than or
the same as the mediastinum, 3 uptake higher than the medi-
astinum but lower than or the same as the liver, 4 uptake
moderately higher than the liver, and 5 uptake markedly
higher than the liver. FDG PET images were analysed in the
axial plane with a slice thickness of 5 mm and in maximum
intensity projection display for this purpose. Furthermore,
each bone lesion was assessed for the presence or absence of
lysis, sclerosis, cortical destruction, bone marrow replace-
ment, surrounding soft-tissue mass, expansiveness, and verte-
bral collapse (for a vertebral lesion). To that end, full-dose CT
images (either from the FDG PET/CT examination or the CT-
guided bone biopsy planning) were analysed in different
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planes (axial, sagittal and coronal) with the slice thickness in
the range 2 – 5 mm. Additionally, the number of bone lesions
in each patient was dichotomized as one or multiple (i.e. more
than one), as determined on FDG PET/CT.
CT-guided bone biopsy
CT-guided biopsies were performed as part of routine clinical
care by or under the supervision of one of the attending radi-
ologists with at least 3 years experience with this procedure.
All patients underwent core needle biopsy. The core needle
size ranged between 9 and 18 gauge, depending on the pref-
erence of the attending radiologist as determined for each
patient individually.
Histopathological examination
The bone biopsy specimens obtained were first decalcified
(when needed) and then evaluated as part of routine clinical
care by one of the attending pathologists.
Diagnostic analysis
The PPV for malignancy (i.e. number of malignant lesions/
number of all malignant and benign lesions) was calculated
for all biopsied lesions and for lesions with FDG uptake ex-
ceeding liver uptake separately, along with 95 % confidence
intervals (CI). Furthermore, the following factors were com-
pared between malignant and benign lesions, using the Fish-
er's exact test for binary data and the Mann-WhitneyU test for
non-Gaussian continuous and ordinal data:
Patient age: continuous variable
Gender: male vs. female
Reported bone pain: presence vs. absence
Reported weight loss: presence vs. absence
Lesional FDG avidity: according to the five-point grad-
ing scale
CT abnormalities: presence vs. absence of any lesional
CT abnormality
Specific lesional CT characteristics: presence vs. absence
of lysis, sclerosis, cortical destruction, bone marrow re-
placement (this item only scored as positive if a
hyperattenuating soft-tissue mass was clearly visible in
the bone marrow space), surrounding soft-tissue mass,
expansiveness and vertebral collapse
Number of bone lesions: one vs. multiple
All tests were two-sided and P values less than 0.05 were
considered statistically significant. Statistical analyses




Between September 2007 and September 2015, 225 patients
underwent a CT-guided bone biopsy. Of these 225 patients, 83
were excluded because no FDG PET/CT scan was performed
within 1 month of the bone biopsy, 31 were excluded because
of (suspicion of) spondylodiscitis, 4 were excluded because of
(suspicion of) sacroiliitis, 2 were excluded because there was
no or insufficient tissue for histopathological diagnosis as de-
termined by the attending pathologist, 1 was excluded because
the biopsy needle fractured during the procedure as a result of
which no bone tissue was acquired, 1 was excluded because of
radiation therapy between the FDG PET/CTscan and the bone
biopsy, and 1 was excluded because no clear histopathological
diagnosis could be made. Thus, 102 patients (63 men, 39
women, mean age 63.3 years, range 19 – 86 years) were fi-
nally included in this study. The basic characteristics of the
included patients are shown in Table 1. The bone lesions were
located in the iliac bone (43 patients), vertebrae (22), sacrum
(9), ribs (9), femur (6), scapula (5), sternum (4), humerus (3)
and clavicle (1). All lesions that were biopsied had an FDG
avidity score of 3 – 5 according to the five-point scale. Three
patients underwent repeat biopsy because the first biopsy was
inconclusive.
Diagnostic yield
Of the 102 patients with bone lesions that all showed FDG
uptake exceeding mediastinal uptake, bone biopsy showed a
malignant lesion in 91 and a benign lesion in 11, which








Range 19 – 86
Patients receiving chemotherapy during
the 3 months before FDG PET/CT and
CT-guided bone biopsy, n (%)
10 (9.8)
Time between FDG PET/CT and bone biopsy (days)
Mean 8.3
Median 7.0
Range 0 – 31
Patients undergoing FDG PET/CT before
CT-guided bone biopsy, n (%)
92 (90.2)
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Table 2 Types and numbers of
malignant and benign bone
lesions diagnosed
Lesions diagnosed on bone biopsy No. of lesions
Malignant diseases
Lung carcinoma metastasis 44
Breast carcinoma metastasis 11
Myeloma 11
Lymphoma 8
Unspecified carcinoma metastasis 6
Gastrointestinal carcinoma metastasis 4
Renal cell carcinoma metastasis 3
Melanoma metastasis 1
Urinary tract carcinoma metastasis 1
Leiomyosarcoma metastasis 1
Thyroid carcinoma metastasis 1
Benign diseases
Tuberculosis 2
Inflammatory infiltrate of unknown origin 2
Focal red marrow hyperplasia 1
Reactive acetabular bone marrow with multiple macrophages and foreign





Giant cell granuloma 1
Gout 1
Table 3 Patient and imaging characteristics in patients with malignant and benign bone lesions and corresponding positive and negative predictive
values for malignancy






Age (years), median 67.0a 52.0 0.044b 47/51 (92.2 %)d 7/51 (13.7 %)d
Male sex 58/91 (63.7 %) 5/11 (45.5 %) 0.326c 58/63 (92.1 %) 6/39 (15.4 %)
Bone pain 60/91 (65.9 %) 6/11 (54.5 %) 0.512c 60/66 (90.9 %) 5/36 (13.9 %)
Weight loss 25/91 (27.5 %) 4/11 (36.4 %) 0.503c 25/29 (86.2 %) 7/73 (9.6 %)
CT abnormal 77/91 (84.6 %) 7/11 (63.6 %) 0.101c 77/84 (91.7 % ) 4/18 (22.2 %)
CT lytic 67/91 (73.6 %) 5/11 (45.5 %) 0.078c 67/72 (93.1 %) 6/30 (20 %)
CT sclerotic 30/91 (33.0 %) 3/11 (27.3 %) 1.000c 30/33 (90.9 %) 8/69 (11.6 %)
CT cortical destruction 54/91 (59.3 %) 3/11 (27.3 %) 0.056c 54/57 (94.7 %) 8/45 (17.8 %)
CT marrow replacement 47/91 (51.6 %) 1/11 (9.1 %) 0.009c 47/48 (97.9 %) 10/54 (18.5 %)
CT surrounding soft tissue mass 24/91 (26.4 %) 0/11 (0.0 %) 0.063c 24/24 (100.0 %) 11/78 (14.1 %)
CT expansive 33/91 (36.3 %) 0/11 (0.0 %) 0.015c 33/33 (100.0 %) 11/69 (15.9 %)
CT vertebral deformity 8/91 (8.8 %) 1/11 (9.1 %) 1.000c 8/9 (88.9 %) 10/93 (10.8 %)
FDG avidity (five-point scale) 3 8 (8.8 %) 0 (0.0 %) 0.096b –e
4 11 (12.1 %) 0 (0.0 %)
5 72 (79.1 %) 11 (100.0 %)
Multifocal bone lesions on FDG PET/CT 73/91 (80.2 %) 5/11 (45.5 %) 0.019c 73/78 (93.6 %) 6/24 (25.0 %)
aNot normally distributed according to Kolmogorov-Smirnov test (P< 0.001)
bMann-Whitney U test
c Fisher’s exact test
d Age dichotomized using the median
e Analysis not performed because FDG avidity score could not be dichotomized
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yielding a PPV for malignancy of 89.2 % (95 % CI
81.7 – 93.9 %). Table 2 shows the types and numbers of
malignant and benign bone lesions diagnosed. Of note, two
patients with a known cancer (prostate cancer in both) were
diagnosed with another cancer based on the bone biopsy (lung
carcinoma metastasis in both). Of the 94 patients with bone
lesions with FDG uptake exceeding liver uptake, bone biopsy
showed a malignant lesion in 83 and a benign lesion in 11,
which yielding a PPV for malignancy of 88.3 % (95 % CI
80.1 – 93.5 %). Higher age, bone marrow replacement of the
lesion on the CT scan, expansion of the lesion on the CT scan,
and presence of multifocal lesions on the FDG PET/CT scan
were significantly more frequent in patients with malignant
than in those with benign bone lesions (P=0.044, P=0.009,
P=0.015, and P=0.019, respectively). Other patient and
imaging characteristics were not found to be significant-
ly different between patients with malignant and those
with benign lesions, although there was a trend towards
more frequent cortical destruction (P= 0.056) and sur-
rounding soft -issue mass (P= 0.063) in malignant bone
lesions (Table 3). Representative examples are shown in
Figs. 1, 2, and 3.
Discussion
The results of this study show that although the vast majority
of bone lesions identified on FDG PET/CT that are referred
for CT-guided bone biopsy because of the suspicion of malig-
nancy are indeed malignant, there is still a non-negligible
number of bone lesions that prove to be benign. Importantly,
this notion also applies to bone lesions that are highly FDG-
avid, i.e. with FDG uptake exceeding liver uptake. Thus, FDG
PET/CT appears to be insufficiently specific to (partially) re-
place CT-guided bone biopsy to confirm malignancy. Interest-
ingly, higher age, bone marrow replacement of the lesion seen
on CT, expansion of the lesion seen on CT, and presence of
multifocal lesions on FDG PET/CT were significantly more
frequent in malignant than in benign bone lesions. There was
also trend towards a significantly higher frequency of cortical
destruction and surrounding soft tissue mass in malignant
bone lesions. This information may be helpful to determine
the most likely imaging-based diagnosis if bone biopsy cannot
be performed for whatever reason.
A limited number of previous studies on this topic have been
performed. Toomayan and Major [9] retrospectively reviewed
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Fig. 1 A 46-year-old man presented with severe back pain. MRI of the
lumbar spine (not shown) demonstrated multiple vertebral bone lesions,
suspicious for bone metastatic disease. a The coronal maximum intensity
projection FDG PET image shows multiple FDG-avid bone lesions in the
left proximal humerus, left-sided ribs, multiple vertebrae, sacrum, iliac
wings, and right proximal femur (arrowheads). Also note an FDG-avid
lesion in the right lower lobe (arrow) with ipsilateral mediastinal
lymphadenopathy (encircled). b, c The axial FDG PET image (b) and
the corresponding CT image with soft tissue settings (c) at the level of the
pelvis show FDG-avid lesions in the sacrum (arrowhead) and right
anterior iliac crest (arrows), the latter with bone marrow replacement
and expansiveness, features that were found to be significantly more
frequent in malignant than in benign lesions. d The right anterior iliac
crest lesion was biopsied under CT guidance. e–j Histopathological
specimens (e–g H&E staining, h–j immunohistochemical staining): e
several fragments of tissue in a background of fresh blood, but no bone
(original magnification ×25); f larger fragment with several epithelial
structures and a desmoplastic background (original magnification
×100); g detail shows clusters and tubules of medium large epithelioid
cells with partly amphophilic cytoplasm and mostly hyperchromatic,
polygonal atypical nuclei, set in a dense desmoplastic stroma, consistent
with (metastatic) adenocarcinoma (original magnification ×400); h–j the
adenocarcinoma stains positive for the broad spectrum cytokeratin
MNF116 (h original magnification ×200), for cytokeratin 7 (i), and for
CEA (j), but CK20, cdx2, TTF-1, p501s and PSA were negative (not
shown). Despite the negative TTF-1, the diagnosis of metastatic lung
adenocarcinoma could be established
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all CT-guided bone biopsies performed at their institution over a
period of 3 years in patients with a history of a single biopsy-
proven malignancy. Of 93 included patients, 82 (88 %) showed
skeletal involvement by the known malignancy, 7 showed a
new malignancy, and 4 (4 %) showed no malignancy. Thus
biopsy of a suspicious skeletal lesion in a patients with a solitary
known malignancy revealed a new malignancy or no evidence
of malignancy in 12 % of patients, emphasizing the importance
of biopsy. However, Toomayan andMajor [9] did not assess the
role of FDG PET/CT in this setting.
In another study, Taira et al. [7] retrospectively reviewed
the FDG PET/CT reports in 59 patients with a histopatholog-
ically proven malignancy, who had a total of 113 bone lesions.
Of 47 bone lesions with positive findings on both FDG PET
and CT, 46 were malignant and 1 was benign, yielding a PPV
of 97.9% (95%CI 88.9 – 99.6%). Of 31 lesions with positive
findings on FDG PET and negative findings on CT, 19 were
malignant and 12 were benign, yielding a PPV of 61.3 %
(95 % CI 43.8 – 76.3 %). Of 35 lesions with negative findings
on FDG PET and positive findings on CT, 6 were malignant
and 29 were benign, yielding a PPV of 17.1 % (95 % CI
8.1 – 32.7 %). Independently, the PPV of FDG PET for all
lesions with positive findings was significantly higher than
that of CT for all lesions with positive findings. The chemo-
therapy status for lesions with positive findings on CTand the
number of lesions per patient was found to significantly asso-
ciated with the PPV of the examinations (P = 0.02 and
P<0.001, respectively). Taira et al. [7] concluded that CT
has a very high PPV for bone metastases (98 %) when the
findings on FDG PET and CT are concordant; however, in
lesions with discordant FDG PET and CT findings in the in-
tegrated examination, PPV is markedly diminished. Major
disadvantages of the study by Taira et al. [7], however, are







Fig. 2 A 33-year-old woman presented with severe lower back pain.
MRI of the lumbar spine (not shown) demonstrated multiple vertebral
bone lesions, suspicious for bone metastatic disease. a The coronal
maximum intensity projection FDG PET image shows multiple FDG-
avid foci in the sternum, thoracic and lumbosacral spine, and both iliac
wings (arrowheads). b, c The axial FDG PET image (b) and the
corresponding CT image with bone window settings (c) at the level of
the pelvis show FDG-avid lesions in the sacrum (arrowhead) and left
posterior iliac crest (arrows), the latter with a sclerotic appearance. d
The left posterior iliac crest lesion was biopsied under CT guidance. e–
h Histopathological specimens (H&E staining): e the centre of the bone
biopsy shows the transition between pre-existing haematopoietic bone
marrow in the upper right third and extensive inflammatory infiltrate in
the lower left two thirds; the diameter of the bony trabeculae (light pink)
varies, and the layering of the trabeculae can be discerned (original mag-
nification ×25); f enlargement shows several areas of necrosis, most
prominent in the upper left, and a cluster of multinucleated giant cells
(arrow) (original magnification ×50). g further enlargement of the same
area (original magnification ×400); h sharply delineated granuloma
surrounded by pre-existing haematopoietic bone marrow is also
demonstrated (original magnification ×200). Ziehl-Neelsen staining for
acid-fast bacillae on the biopsy was negative (not shown), but the
Mantoux skin test was strongly positive with blistering. Therefore, the
diagnosis of bone tuberculosis could be established
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majority of cases (only 13 of 113 lesions were histopatholog-
ically assessed), and the lack of standardized FDG PET and
CT criteria. Therefore, the validity and applicability of their
results are questionable.
In yet another study, Nguyen et al. [8] retrospectively
searched their radiology procedure database for all FDG
PET-positive lesions that were biopsied under imaging-guid-
ance. Of 26 biopsied bone lesions, 25 proved to be malignant,
yielding a PPVof 96.2 % (95 % CI 81.1 – 99.3 %). However,
the study by Nguyen et al. [8] was limited by a small sample
size and also lacked a clear definition of FDG PET positivity.
Unlike previous research, the present study included the larg-
est sample size of patients who had all undergone both FDG
PET/CT (which was interpreted with standardized criteria)
and CT-guided bone biopsy followed by histopathological
examination, which allowed more solid conclusions to be
drawn on the roles of these diagnostic procedures with respect
to the assessment of (suspicious) bone lesions.
This study had several limitations. First, the study was per-
formed in a large hospital centrally located in The Netherlands,
as a result of which the results are only applicable to a similar
(Western) population. In non-Western countries, the PPV for
malignancy of suspicious biopsied FDG-avid bone lesions
may be lower, for example due to the higher prevalence of
(bone) tuberculosis in such countries. Furthermore, the results
are not applicable to primary bone tumours, because these
were not included in the present study. In addition, no paedi-
atric patients were included. Second, due to the retrospective
nature of this study, only patients who underwent FDG PET/
CT and who were referred for CT-guided biopsy were includ-
ed, which may have introduced both selection and verification
bias. Third, 10 of 102 patients received chemotherapy during
the 3 months before FDG PET/CTand CT-guided bone biopsy
(but not between the two procedures), which may have affect-
ed FDG uptake in bone.However, this reflects clinical practice,








Fig. 3 A 58-year-old man who was treated with DHAP-VIM-DHAP
(DHAP, cisplatin-cytarabine-dexamethasone; VIM, etoposide-
ifosfamide-methotrexate) before autologous stem cell transplantation
because of relapsed peripheral T-cell non-Hodgkin lymphoma. a The
coronal maximum intensity projection FDG PET image shows a new
FDG-avid lesion in the left proximal humerus (arrow) that developed
during chemotherapy. b, c The axial FDG PET image (b) and the
corresponding CT image with bone window settings (c) at the level of
the left proximal humerus show the FDG-avid lesion (arrow) without any
clear abnormalities seen on CT. d The lesion was biopsied under CT
guidance. e–h Histopathological specimens (H&E staining): e one of
the larger fragments of the biopsy of the left proximal humerus shows
irregular and enlarged, clearly layered bony trabeculae (original
magnification ×25); the darker portion in the lower area consists of
amorphous eosinophilic material, partially consisting of destroyed bone;
the upper right area shows smeared cells, of which the provenance cannot
be ascertained; f, g enlargement (f original magnification ×50) and further
enlargement (g original magnification ×100) show the apposed rim of
Bnew^ bone; h yet further enlargement (original magnification ×200)
clearly shows the apposed rim of Bnew^ bone, with the central region
of necrotic bone showing empty lacunae (arrows); in the surrounding
apposed lamellar bone a few nuclei (arrowheads) can be seen, which
could fit with (partial) regeneration after avascular necrosis; however,
new woven bone as well as a rim of osteoblasts at the periphery are
missing (stars). Based on these histopathological findings, avascular
necrosis is the most likely diagnosis
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FDG-avid (i.e. FDG uptake score of 3 in two patients, 4 in one
patients, and 5 in seven patients). Fourth, 10 of 102 (9.8 %)
patients underwent CT-guided bone biopsy before FDG
PET/CT, and this may have affected the FDG PET/CT
findings. Fifth, no (semi)quantitative FDG uptake mea-
surements were performed, because two different PET/
CT systems were used during the period of the study, and
it is known that this can significantly affect standardized
uptake value measurements [10]. Sixth, all FDG PET/CT
scans were performed approximately 60 min after FDG
injection. Dual time-point FDG PET has been reported to
be potentially helpful in the differentiation of malignant
tumours from benign ones [11] but this was outside the
scope of this study. Seventh, not all patients had undergone
a contrast-enhanced CT scan. However, it is unlikely that
this affected the CT-based assessment of bone lesions, be-
cause all patients had an available full-dose CT scan.
In conclusion, the PPV for malignancy of suspicious bone
lesions identified on FDG PET/CT is not sufficiently high to
justify changes in patient management without histopatholog-
ical confirmation. Nevertheless, ancillary patient and imaging
characteristics may help to quantify the likelihood of a malig-
nant bone lesion.
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